期刊文献+

聚乙二醇干扰素α-2а对慢性乙型肝炎肝纤维化的疗效观察 被引量:3

下载PDF
导出
摘要 目的:观察聚乙二醇干扰素α-2а对慢性乙型肝炎肝纤维化患者的治疗效果。方法:观察组36例用聚乙二醇干扰素α-2а治疗48周,对照组24例给予常规护肝治疗48周。观察治疗前后肝功能、肝纤维化指标的变化。结果:两组治疗后血清丙氨酸转氨酶(ALT)、门冬氨酸转氨酶(AST)、HBeAg、HBV-DNA及血清肝纤维化4项指标均明显改善,但观察组改善程度明显优于对照组(P<0.01)。结论:聚乙二醇干扰素α-2а注射液具有良好的抗病毒及抗纤维化作用。
作者 吴颖
出处 《交通医学》 2009年第4期376-377,共2页 Medical Journal of Communications
  • 引文网络
  • 相关文献

参考文献4

  • 1第五次全国传染病寄生虫病学术会议.病毒性肝炎诊断标准[J].中西医结合肝病杂志,1996,6(1):50-53.
  • 2Lok AS, McMahon BJ.Chronic hepatitis B [J]. Hepatology, 2007,45 (2) : 507-539.
  • 3万谟彬,翁心华.干扰素治疗慢性乙型肝炎专家建议[J].中华传染病杂志,2007,25(10):577-583. 被引量:48
  • 4Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha 2a(40 kDa):an advance in the treatment of hepatitis B e antigen positive chronic hepatitis B[J].J Viral Hepat,2003, 10(4) :298-305.

二级参考文献9

  • 1慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 2Lok AS, McMahon BJ. Chronic hepalitis B. Hepalology, 2007, 45:507-539.
  • 3Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa) : an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10 : 298-305.
  • 4Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa 2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Egngl J Med, 2005, 352:2682-2695.
  • 5Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351:1206-1217.
  • 6Lau GK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alpha-2a(40KD)[PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatology, 2006, 44 Suppl 2:S23-S24.
  • 7Marcellin P, Bonino F, Lau GK, et al. Virological and biochemi-cal response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a(40 kD) + lamivudine: 3-year follow-up resuits. J Hepatology, 2007, 46 Suppl 1:S25-S26.
  • 8Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine Globe Trial : Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology, 2006, 44(Suppl):230A 231A.
  • 9Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepa titis B: summary of a clinical research workshop. Hepatology, 2007, 45:1056-1075.

共引文献53

同被引文献31

引证文献3

二级引证文献13

;
使用帮助 返回顶部